Opinion|Videos|April 11, 2025
Determining Follow-Up Approach in Melanoma Based on GEP Risk Level
Author(s)David Cotter, MD, PhD
An expert discusses whether the 31-gene expression profile (GEP) risk classification would change treatment guidelines and how the patient’s GEP risk level would influence the approach to surveillance and follow-up.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Does the 31-GEP risk classification change your treatment guidelines?
- How would you approach surveillance and follow-up with this patient after knowing their GEP risk level?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Grants Breakthrough Therapy Designation to Litifilimab for Cutaneous Lupus Erythematosus
2
Phase 2b Analysis Shows Consistent Vitiligo Repigmentation With Ritlecitinib
3
On the Horizon: Innovations in the Acne Treatment Pipeline
4
Dual ITK/JAK3 Inhibition Shows Strong Preclinical Activity in Severe Alopecia Areata
5